Abstract
BACKGROUND
The regimens of carboplatin plus paclitaxel (CP) and methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) were compared in patients with advanced urothelial carcinoma.
METHODS
Patients with metastatic urothelial carcinoma were randomized to receive either CP (paclitaxel at a dose of 225 mg/m^2^ and carboplatin [targeted area under the concentration‐time curve (AUC) of 6] given every 21 days) or the standard M‐VAC dosage.
RESULTS
Eighty‐five patients were randomized to the respective treatment regimens (41 to CP and 44 to M‐VAC). Response rates and overall survival were similar for both treatment arms. Patients treated with CP had an overall response rate of 28.2% (95% binomial confidence interval, 15.0–44.9%) compared with an overall response rate of 35.9% for the M‐VAC arm (95% binomial confidence interval, 21.2–52.8%) (P = 0.63, Fisher exact test). The median progression‐free survival among patients who were treated with M‐VAC was 8.7 months and was 5.2 months for patients receiving CP (P = 0.24, log‐rank test). At a median follow‐up of 32.5 months, the median survival for patients treated with M‐VAC was 15.4 months versus 13.8 months for patients treated with CP (P = 0.65, log‐rank test). Patients treated with M‐VAC were found to have more severe worst‐degree toxicities compared with patients treated with CP (P = 0.0001). There were no significant differences with regard to quality of life as assessed by the Functional Assessment of Cancer Therapy–Bladder (FACT‐BL) instrument (P = 0.33).
CONCLUSIONS
Interpretation of the results of this study must be made with caution because the study failed to reach its accrual goal. Patients treated with CP had a median survival of 13.8 months compared with 15.4 months for patients treated with M‐VAC. Patients treated with CP appeared in general to better tolerate their treatment; however, there were no significant differences noted with regard to measured quality of life parameters. Cancer 2004. © 2004 American Cancer Society.